Garcinia Mangostana Extracts in the Management of Weight Loss

• Sponsor: University of Roma La Sapienza
• Information provided by (Responsible Party): Carla Lubrano, University of Roma La Sapienza

Study Description

Brief Summary:

Obesity is one of the greatest public health challenges of the 21st century. Its prevalence has tripled in many countries of the European Region since the 1980s, and the numbers of those affected continue to rise at an alarming rate. In addition to causing various physical disabilities and psychological problems, excess weight drastically increases a person's risk of developing a number of noncommunicable diseases including cardiovascular disease, cancer and diabetes, in association or not to metabolic syndrome. The risk of developing more than one of these diseases (co-morbidity) also increases with increasing body weight. Every year a growing number of patient tend to suffer of more severe obesity and difficulty in losing weight even with a restricted diet and exercise.

Garcinia mangostana (Sphaeranthus indicus extract) has known for its antioxidant properties; new evidence point out some promising effects in the prevention of lipogenesis and the promotion of lipolysis . Currently in the scientific literature there is only one paper, by Stern et al., showing the association of Garcinia mangostana assumption in low-calorie diet. This work has demonstrated a significant reduction in weight loss , compared to the placebo group,due to the use of Garcinia mangostana.

Aim of the present study is the evaluation of safety and efficacy of weight loss in severe obese patients. Also cardiometabolic parameters and flogosys serum indicators will be evaluated before and after 6 month therapy of low calory diet alone or in association with Garcinia mangostana extract.

Condition or disease	Intervention/treatment	Phase
Severe Obesity	Dietary Supplement: Garcinia mangostana; Behavioral: Control group	Phase 4

Detailed Description:

After the screening visit for the evaluation of the inclusion / exclusion criteria and sign informed consent(Visit 1), each patient will be randomized (Visit 2; Time 0; Baseline) (1: 1) to receive two different treatment for the duration of 26 weeks:

1. low-calorie balanced diet consistent exercise (control group)
2. balanced low-calorie diet and regular exercise in combination with the assumption of Garcinia mangostana (treatment group)

Throughout the duration of the study, every eight weeks, unless otherwise indicated from the specialists, for each subject was expected a nutritional and an endocrinological visit with a anthropometric parameter check (body composition) and compliance to therapy (dietary / physical activity diary).

Also a bood sample test was performed to evaluate electrocardiogram, lipid profile, glucose tolerance, hormonal parameters, inflammatory and bone markers.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 40 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Efficacy and Tolerability of Garcinia Mangostana Extracts in the Management of Weight Loss in Severe Obese Patients
• Study Start Date: November 2015
• Actual Primary Completion Date: May 2016
• Actual Study Completion Date: May 2016

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Garcinia mangostana (treatment group); Balanced low-calorie diet and regular exercise in combination with integration	Dietary Supplement: Garcinia mangostana
Control group; balanced low-calorie diet and regular exercise	Behavioral: Control group

Outcome Measures

Primary Outcome Measures :

1. Weight loss - Kg reduction [ Time Frame: 26 weeks ]

Secondary Outcome Measures :

1. Insulin sensitivity assessed by the homeostatic model assessment (HOMA-IR) [ Time Frame: 26 weeks ]
2. Lipid profile by serum biochemistry [ Time Frame: 26 weeks ]
3. Abdominal obesity measured by waist circumference [ Time Frame: 26 weeks ]
4. Body composition by Dexa parameters [ Time Frame: 26 weeks ]
5. Changes in microalbuminuria by unin analysis [ Time Frame: 26 weeks ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Obesity: BMI >35 kg/m2.
• Stable medical therapy for comorbidities from at least 6 months

Exclusion Criteria:

• Hormonal replacement therapy
• Hyperprolactinaemia and /or other endocrine hypothalamic-pituitary diseases (empty sella syndrome and expansive pituitary disorders evaluated by MRI)
• Any other condition that medical judgment precludes patient safety

Contacts and Locations

No Contacts or Locations Provided

More Information

• Responsible Party: Carla Lubrano, Professor, University of Roma La Sapienza
• ClinicalTrials.gov Identifier: NCT02823561 History of Changes
• Other Study ID Numbers: URomLS-01
• First Posted: July 6, 2016
• Last Update Posted: August 31, 2016
• Last Verified: June 2016

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Weight Loss; Obesity, Morbid; Body Weight Changes; Body Weight; Signs and Symptoms; Obesity; Overnutrition; Nutrition Disorders; Overweight